Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19651360 | 0.91 | NPC1 (0.44) | ACHESMN1; SMN2KDM4ELMNAPDE10A | |
| SCHEMBL26649401 | 0.90 | DHODH (0.57) | ACHESMN1; SMN2KDM4ELMNAPDE10A | |
| SCHEMBL27939580 | 0.89 | CYP19A1 (0.56) | ACHESMN1; SMN2KDM4ELMNAPDE10A | |
| SCHEMBL26649504 | 0.86 | KMT2A (0.53) | SMN1; SMN2KDM4ELMNAHPGDACP1 | |
| SCHEMBL13568539 | 0.85 | CYP3A4 (0.53) | SMN1; SMN2KDM4ELMNAPDE10ADHODH | |
| SCHEMBL9361568 | 0.85 | MAPT (0.66) | SMN1; SMN2KDM4ELMNAHPGDPOLB | |
| SCHEMBL16099274 | 0.84 | MAPK1 (0.52) | SMN1; SMN2KDM4ELMNADHODHHPGD | |
| SCHEMBL26649316 | 0.84 | DHODH (0.53) | ACHESMN1; SMN2KDM4ELMNAPDE10A | |
| SCHEMBL20561472 | 0.83 | TOP1 (0.55) | SMN1; SMN2KDM4ELMNAHPGDCYP2C9 | |
| SCHEMBL9054831 | 0.81 | KDM4E (0.67) | SMN1; SMN2KDM4ELMNAHPGDACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100797-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | claimed |
| US-6372736-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-04-16 | — | — | US | claimed |
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | claimed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | claimed |
| WO-2023219456-A1 | QUINOLINE-BASED HISTONE DEACETYLASE INHIBITORY SUBSTANCES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS ACTIVE INGREDIENT | 숙명여자대학교 산학협력단 | 2023-11-16 | — | — | WO | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| CN-105102442-B | Quinoline as anticarcinogen | 基因科学医药公司 | 2018-11-09 | — | — | CN | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9493436-B2 | Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of Mycobacterium tuberculosis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493436-B2 | Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of Mycobacterium tuberculosis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| EP-1089958-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6133409-A | REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000013681-A2 | 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (I) | VERNALIS RESEARCH LIMITED (GB) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
| CN-1240418-A | Solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds | RHONE POULENC RORER PHARMA (US) | 2000-01-05 | — | — | CN | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0946478-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998029376-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | ACHE 2115/4885SMN1; SMN2 3931/4885KDM4E 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.